Vor Biopharma pivots to telitacicept for autoimmune diseases, backed by $491M cash to 2029. Click here to read an analysis of ...

Summary: A new study has completely revived and expanded this lost chapter of human evolution. Leveraging modern molecular genetic dating and advanced phylogenetic statistical modeling, researchers ...

Travere Therapeutics has transitioned into a rare disease commercial platform, driven by FILSPARI’s growth in IgAN and recent FSGS approval. More on TVTX stock.

James Chen, CMT is an expert trader, investment adviser, and global market strategist. Cierra Murry is an expert in banking, credit cards, investing, loans, mortgages, and real estate. She is a ...